blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2886122

EP2886122 - AGENT FOR TREATING CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.01.2020
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  25.01.2019
FormerGrant of patent is intended
Status updated on  28.10.2018
FormerExamination is in progress
Status updated on  10.11.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
National Cancer Center
1-1, Tsukiji 5-Chome
Chuo-ku
Tokyo 104-0045 / JP
For all designated states
Asahi Kasei Pharma Corporation
1-105 Kanda Jinbocho Chiyoda-ku
Tokyo 101-8101 / JP
[2015/26]
Inventor(s)01 / OCHIYA Takahiro
National Cancer Center
1-1 Tsukiji 5-chome
Chuo-ku
Tokyo 104-0045 / JP
02 / TAKESHITA, Fumitaka
National Cancer Center
1-1, Tsukiji 5-chome
Chuo-ku
Tokyo 1040045 / JP
 [2015/26]
Representative(s)Forstmeyer, Dietmar, et al
Boeters & Lieck
Oberanger 32
80331 München / DE
[N/P]
Former [2015/26]Forstmeyer, Dietmar, et al
BOETERS & LIECK
Oberanger 32
80331 München / DE
Application number, filing date13830540.419.08.2013
[2019/09]
WO2013JP72064
Priority number, dateJP2012018191520.08.2012         Original published format: JP 2012181915
[2015/26]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014030602
Date:27.02.2014
Language:JA
[2014/09]
Type: A1 Application with search report 
No.:EP2886122
Date:24.06.2015
Language:EN
[2015/26]
Type: B1 Patent specification 
No.:EP2886122
Date:27.02.2019
Language:EN
[2019/09]
Search report(s)International search report - published on:JP27.02.2014
(Supplementary) European search report - dispatched on:EP15.04.2016
ClassificationIPC:A61K31/7105, A61K31/7088, A61K31/713, A61K48/00, A61P13/10, A61P35/00, A61P35/04, C12Q1/68, G01N33/15, G01N33/50, C12N15/09
[2015/26]
CPC:
C12N15/113 (EP,US); A61K48/00 (KR); A61K31/7105 (EP,US);
A61K31/713 (KR); A61P13/10 (EP); A61P35/00 (EP,KR);
A61P35/04 (EP); C12Q1/6886 (EP,KR,US); G01N33/5011 (EP,US);
G01N33/57407 (EP,US); C12N2310/113 (EP,US); C12N2310/14 (EP,US);
C12N2310/141 (US); C12N2320/30 (US); C12Q2600/106 (US);
C12Q2600/136 (US); C12Q2600/158 (EP,US); C12Q2600/178 (EP,US) (-)
C-Set:
C12N2310/141, C12N2330/10 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/26]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:MITTEL ZUR BEHANDLUNG VON KREBS[2015/26]
English:AGENT FOR TREATING CANCER[2015/26]
French:AGENT POUR LE TRAITEMENT DU CANCER[2015/26]
Entry into regional phase16.02.2015Translation filed 
16.02.2015National basic fee paid 
16.02.2015Search fee paid 
16.02.2015Designation fee(s) paid 
16.02.2015Examination fee paid 
Examination procedure16.02.2015Examination requested  [2015/26]
09.09.2016Amendment by applicant (claims and/or description)
13.11.2017Despatch of a communication from the examining division (Time limit: M04)
07.02.2018Reply to a communication from the examining division
25.04.2018Despatch of a communication from the examining division (Time limit: M04)
11.07.2018Reply to a communication from the examining division
29.10.2018Communication of intention to grant the patent
09.01.2019Fee for grant paid
09.01.2019Fee for publishing/printing paid
09.01.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.11.2017
Opposition(s)28.11.2019No opposition filed within time limit [2020/06]
Fees paidRenewal fee
05.08.2015Renewal fee patent year 03
25.08.2016Renewal fee patent year 04
23.08.2017Renewal fee patent year 05
24.08.2018Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.08.2013
AL27.02.2019
AT27.02.2019
CY27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
MC27.02.2019
MK27.02.2019
MT27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SI27.02.2019
SK27.02.2019
SM27.02.2019
TR27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
IE19.08.2019
LU19.08.2019
BE31.08.2019
CH31.08.2019
LI31.08.2019
[2022/31]
Former [2021/34]HU19.08.2013
AL27.02.2019
AT27.02.2019
CY27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
MC27.02.2019
MT27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SI27.02.2019
SK27.02.2019
SM27.02.2019
TR27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
IE19.08.2019
LU19.08.2019
BE31.08.2019
CH31.08.2019
LI31.08.2019
Former [2021/32]HU19.08.2013
AL27.02.2019
AT27.02.2019
CY27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
MC27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SI27.02.2019
SK27.02.2019
SM27.02.2019
TR27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
IE19.08.2019
LU19.08.2019
BE31.08.2019
CH31.08.2019
LI31.08.2019
Former [2021/26]AL27.02.2019
AT27.02.2019
CY27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
MC27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SI27.02.2019
SK27.02.2019
SM27.02.2019
TR27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
IE19.08.2019
LU19.08.2019
BE31.08.2019
CH31.08.2019
LI31.08.2019
Former [2020/38]AL27.02.2019
AT27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
MC27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SI27.02.2019
SK27.02.2019
SM27.02.2019
TR27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
IE19.08.2019
LU19.08.2019
BE31.08.2019
CH31.08.2019
LI31.08.2019
Former [2020/36]AL27.02.2019
AT27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
MC27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SI27.02.2019
SK27.02.2019
SM27.02.2019
TR27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
IE19.08.2019
LU19.08.2019
CH31.08.2019
LI31.08.2019
Former [2020/25]AL27.02.2019
AT27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
MC27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SI27.02.2019
SK27.02.2019
SM27.02.2019
TR27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
LU19.08.2019
CH31.08.2019
LI31.08.2019
Former [2020/17]AL27.02.2019
AT27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SI27.02.2019
SK27.02.2019
SM27.02.2019
TR27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2020/13]AL27.02.2019
AT27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SI27.02.2019
SK27.02.2019
SM27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2020/03]AL27.02.2019
AT27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SK27.02.2019
SM27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2019/52]AL27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SK27.02.2019
SM27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2019/49]AL27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
NL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SK27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2019/48]DK27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
NL27.02.2019
RS27.02.2019
SE27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2019/47]ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
NL27.02.2019
RS27.02.2019
SE27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2019/46]FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
NL27.02.2019
RS27.02.2019
SE27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2019/39]FI27.02.2019
HR27.02.2019
LT27.02.2019
LV27.02.2019
NL27.02.2019
RS27.02.2019
SE27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2019/38]FI27.02.2019
LT27.02.2019
NL27.02.2019
SE27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
PT27.06.2019
Former [2019/37]FI27.02.2019
LT27.02.2019
NL27.02.2019
SE27.02.2019
NO27.05.2019
GR28.05.2019
PT27.06.2019
Former [2019/34]FI27.02.2019
LT27.02.2019
NL27.02.2019
SE27.02.2019
NO27.05.2019
PT27.06.2019
Former [2019/33]FI27.02.2019
LT27.02.2019
NO27.05.2019
PT27.06.2019
Documents cited:Search[A]  - JAMES W F CATTO ET AL, "MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review", EUROPEAN UROLOGY, ELSEVIER BV, NL, vol. 59, no. 5, doi:10.1016/J.EURURO.2011.01.044, ISSN 0302-2838, (20110124), pages 671 - 681, (20110125), XP028160335 [A] 1-25

DOI:   http://dx.doi.org/10.1016/j.eururo.2011.01.044
International search[A]  - ZHENG B ET AL., "MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer", CLIN CANCER RES, (201112), vol. 17, no. 24, pages 7574 - 7583, XP055188583

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-11-1714
 [A]  - SETH S ET AL., "RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer", MOL THER, (201105), vol. 19, no. 5, pages 928 - 935, XP055188584

DOI:   http://dx.doi.org/10.1038/mt.2011.21
 [A]  - HUANG L ET AL., "MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3", INT J CANCER, (20110415), vol. 128, no. 8, pages 1758 - 1769, XP055188585

DOI:   http://dx.doi.org/10.1002/ijc.25509
 [A]  - LOPEZ JA ET AL., "Differential effects of miR-34c -3p and miR-34c-5p on SiHa cells proliferation apoptosis, migration and invasion", BIOCHEM BIOPHYS RES COMMUN, (20110610), vol. 409, no. 3, pages 513 - 519, XP055188586

DOI:   http://dx.doi.org/10.1016/j.bbrc.2011.05.036
 [A]  - KUOKKANEN S ET AL., "Genomic profiling of microRNAs and messenger RNAs reveals hormonal regulation in microRNA expression in human endometrium", BIOL REPROD, (201004), vol. 82, no. 4, pages 791 - 801, XP055188588

DOI:   http://dx.doi.org/10.1095/biolreprod.109.081059
 [A]  - HURST CD, "High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization", ONCOGENE, (2004), vol. 23, no. 12, pages 2250 - 2263, XP055188591

DOI:   http://dx.doi.org/10.1038/sj.onc.1207260
 [XP]  - UCHINO K ET AL., "Therapeutic Effects of MicroRNA -582-5p and -3p on the Inhibition of Bladder Cancer Progression", MOLECULAR THERAPY, (201303), vol. 21, pages 610 - 619, XP055188593

DOI:   http://dx.doi.org/10.1038/mt.2012.269
ExaminationWO2008103135
 EP2133431
    - "Human miRNA detecting probe sequence, SEQ ID 956.", Geneseq, (20081030), Database accession no. ATF55927, URL: EBI
    - BUTZ HENRIETT ET AL, "MicroRNA profile indicates downregulation of the TGF[beta] pathway in sporadic non-functioning pituitary adenomas", PITUITARY, KLUWER, BOSTON, US, vol. 14, no. 2, doi:10.1007/S11102-010-0268-X, ISSN 1386-341X, (20101110), pages 112 - 124, (20101110), XP036206110

DOI:   http://dx.doi.org/10.1007/s11102-010-0268-x
by applicantJP2006506469
 JP2008086201
    - ELBASHIR SM ET AL., NATURE, (2001), vol. 411, pages 494 - 498
    - SCIENCE, (2004), vol. 303, pages 83 - 86
    - PROC. NATL. ACAD. SCI., (2006), vol. 103, pages 3687 - 3692
    - CELL BIOL. INT., (2010), vol. 34, pages 815 - 826
    - FEBS LETT., (2011), vol. 585, pages 2165 - 2170
    - CANCER SCI., (2009), vol. 100, pages 1801 - 1808
    - MOL. CANCER. RES., (2008), vol. 6, pages 372 - 382
    - PROC. NATL. ACAD. SCI., (2007), vol. 104, pages 19291 - 6
    - CURR. TOP. MED. CHEM., (2006), vol. 6, pages 913 - 25
    - MOL. BIOSYST., (2010), vol. 6, pages 862 - 70
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.